Stadol
(Butorphanol)ApprovedSmall molecule
Bristol-Myers SquibbStadol is one of 60 small molecule programs targeting Agitation. It is currently in Approved.
4
Indications
9
Total Trials
0
Active Trials
59
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
83 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Stadol
Bristol-Myers SquibbApproved
Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Dynastat
PfizerPreclinical
Proamatine
TakedaPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sedation2 trials
Hyperalgesia1 trial
Agitation1 trial
Esketamine1 trial
Esketamine and Butorphanol for Post-Lobectomy Pain
Completed·—·Phase 4·NCT06398834·223 enrolled
3 more indications
Visceral Pain1 trial
Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain
Completed·—·Phase 4·NCT04477733·203 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
STADOL
NDA NDA017857
Dec 12, 1991
STADOL
NDA NDA019890
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Butorphanol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company